BSF 208075

Known as: (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic Acid, BSF-208075, BSF208075 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2007
0120012007

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
UNLABELLED Leukocytes contribute to the ischemia-reperfusion injury. Recent studies suggested endothelins could be important… (More)
Is this relevant?
2005
2005
Endothelin (ET) contributes to disturbances of hepatic microcirculation after ischemia/reperfusion (I/ R) by causing… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
Due to increased capillary permeability and the early appearance of vasoactive and toxic agents, patients suffering from… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2002
2002
Mice with a genetic deletion of the atrial natriuretic peptide (ANP) receptor, guanylyl cyclase A (GC-A -/-), have chronic… (More)
Is this relevant?
Review
2002
Review
2002
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly… (More)
Is this relevant?